The Life Sciences Innovative Manufacturing Fund (LSIMF)
Department for Science, Innovation and Technology
What it funds
The Life Sciences Innovative Manufacturing Fund (LSIMF) is a capital grants fund which aims to build resilience for future health emergencies and capitalise on the UK’s world-leading research and development capabilities. The fund will enhance and accelerate affordable access to mature, new and emerging Life Sciences products for both pandemic and non-pandemic scenarios.LSIMF will provide up to £520 million in capital grants for investment in the manufacture of human medicines and medical techno
Who can apply
Your companyTo be eligible to apply for the fund, your company must be:A UK registered company, or a UK registered establishmentUK establishments must also have at least one UK registered company in their group structureA wholly private sector businessA product developer, contract development manufacturing organisation, or a generics manufacturer.Applicants must also be able to provide two years of audited accounts for the applicant company (and/or if applicable, parent entity). If this is not available – for example because the company is not required by Companies House to submit audited accounts – we will ask for demonstration that the remaining funding required for the project to go ahead is available. You may be also asked for evidence that your company (or if applicable, parent entity) has a track record of successfully manufacturing medicines or medical devices in the UK or abroad, or that you have successfully developed a product intended for commercial scale-up.Your project To be eligible for the fund, your project must:Have a total eligible cost of at least £8 million. Eligible costs include capital, R&D and skills/training expenditure. This should exclude operational expe
How to apply
How to applyLSIMF is now open for EOIs. Please click the button above to complete and submit your EOI form. If you have any questions, please contact LSIMF@officeforlifesciences.gov.uk. The LSIMF application process is comprised of three parts:The Expression of Interest (EOI) – we will use the EOI to evaluate your basic eligibility and identify projects that align with the Fund objectives. Eligible projects will be invited to the next stage. We are open to EOIs on a rolling basis, but submission does not constitute an application into LSIMF.Health resilience assessment – we will assess the health resilience benefits of your project:Application form 1 – application windows will open on a quarterly basis. Eligible applicants will be invited to complete application form 1. Here, you will be asked to describe the health resilience benefits of your project. This stage is assessed by a panel o
Last checked against the official source within the last 7 days. Scheme parameters are set by the funder and can change — verify before applying, or let us do it for you.
Related schemes
Innovate UK Grant Competitions
Innovate UK
Rolling portfolio of themed R&D grant competitions for UK businesses, typically funding 25-70% of project costs across feasibility, industrial research and experimental development.
Knowledge Transfer Partnerships (KTP)
Innovate UK / UKRI
Funds a high-calibre graduate (Associate) plus academic team embedded in your business for 12-36 months to deliver a strategic innovation project. SMEs typically pay ~33% of project costs.
R&D Tax Relief (Merged Scheme & ERIS)
HMRC
Corporation tax relief on qualifying R&D expenditure. Merged scheme gives a 20% above-the-line credit (~15-16% net); loss-making R&D-intensive SMEs can claim enhanced support (ERIS) worth up to ~27p per £1 of qualifying spend.